IND-enabling studies of an antisense oligonucleotide therapy for CLN3 batten disease

Active Cooperative Agreement Awarded

Award ID
U01NS148918
Recipient
Awarding agency
Obligated
$1,347,673

Award facts

Completion date 12% complete
Place of performance
Ann Arbor, MI 48109, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Neurological Disorders and Stroke awarded Regents of the University of Michigan $1,347,673 in obligated funding under Cooperative Agreement U01NS148918 on July 14, 2026. The award falls under the National Center for Advancing Translational Sciences program (CFDA 93.350).

The recipient will fund investigational new drug (IND)-enabling studies of an antisense oligonucleotide (ASO) therapy for CLN3 Batten disease. The project targets the CLN3EX7/8 variant. The team's prior frame-shift-correcting ASO has been given intrathecally to two children with a different CLN3 variant, and this project proposes an ASO that induces exon 5 skipping to produce a naturally occurring in-frame CLN3 isoform. The source cites pre-clinical proof-of-concept evidence from a knock-in mouse model and from ASO studies in pig and mouse.

Rosalind Franklin University of Medicine & Science is the sub-recipient, under sub-award U01NS148918-SUBK00024564 dated October 28, 2026. It will conduct preclinical efficacy and safety studies of the lead exon 5-skipping ASO candidates. The work includes off-target hybridization assessment, targeted splicing assays for unintended alterations, evaluation of isoform stability and function, and compilation of preclinical data and study reports for an IND dossier, prepared with regulatory consultants.

The ultimate completion date is June 30, 2029. Place of performance is Ann Arbor, Michigan 48109.

Description

Abstract
Genomic deletion of exons 7 and 8 from the CLN3 gene is the most common cause of CLN3 batten disease (omim #204200), a rare autosomal recessive, lethal, neurodegenerative lysosomal storage disorder. The function of the protein is not known, but the loss of its function and, potentially the consequent production of a toxic protein fragment, is associated with accumulation of auto-fluorescent storage material and glycerophosphodiesters (GPDS) in cells, and progressive vision loss, cognitive decline, motor coordination dysfunction, seizures, dystonia and ultimately death in children and young adults. The median lifespan of those with CLN3 disease is 20-30 years. DR. Hastings and the team involved in this proposal have developed an antisense oligonucleotide (ASO) medicine for two children with CLN3 disease caused by a different variant, C.569DUPG, which causes an open reading frame shift resulting in a premature termination codon (PTC). The ASO induces exon skipping of exon 8 to remove the frameshift and rescue CLN3 protein expression, albeit via an alternative, naturally occurring isoform. The children were treated with this ASO by intrathecal injection and are responding remarkably well to this ASO therapy, called zebronkysen, exhibiting a reduction in disease symptoms and GPDS in the cerebrospinal fluid. On the success of this first frame-shift-correcting ASO medicine, we propose now to develop a similar approach for the more common CLN3 disease-causing variant CLN3EX7/8, which has a premature termination codon in exon 9. In this case, we have developed an ASO that induces skipping of exon 5, which results in a naturally occurring in-frame, CLN3 isoform, CLN3EX5/7/8. We have generated extensive pre-clinical, proof-of-concept evidence that conversion of CLN3EX7/8 to CLN3EX5/7/8 either genetically, in a knock-in mouse model or using asos in PIG and mouse with the CLN3EX7/8 mutation, results in lower disease burden. This project aims to establish the safety and pharmacodynamic profile of the ASO drug, support its manufacturing, and prepare an investigational new drug application in preparation for a clinical trial to initially treat two children with the disease, with a long-term goal of creating an ASO therapy for all children with the most common cause of CLN3 batten disease.

Transactions

Action Obligated Date
Amendment $947,673
Original award $400,000

Subawards

Subrecipient Amount Awarded
Rosalind Franklin University Of Medicine & Science The proposed project centers on the development of antisense oligonucleotides (ASOs) as a therapeutic strategy for theCLN3Δex7/8 pathogenic variant in CLN3… $97,556

Quick answers

Who received award U01NS148918?

U01NS148918 was awarded to Regents Of The University Of Michigan by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on July 14, 2026.

How much is award U01NS148918 worth?

$1,347,673 has been obligated on U01NS148918.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award